RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study

INTRODUCTION: Rivaroxaban is a direct factor Xa inhibitor used once a day for prevention of thrombotic events in patients with atrial fibrillation (AF). However, in a small proportion of subjects thrombus in the left atrial appendage (LAA) is present despite this treatment. The aim of this study was...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arch Med Sci
Asıl Yazarlar: Piotrowski, Roman, Zaborska, Beata, Pilichowska-Paszkiet, Ewa, Sikora-Frąc, Małgorzata, Baran, Jakub, Kułakowski, Piotr
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Termedia Publishing House 2019
Konular:
Clinical Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7069443/
https://ncbi.nlm.nih.gov/pubmed/32190138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2019.86616
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller